Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Sorrento Announces Drilling Contract & Receives Permit to Drill Bottom Brook Project (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News eXoZymes Inc EXOZ

Healthcare Biotechnology
eXoZymes, Inc. operates as a development stage biotechnology company. The company focuses on the development of enzyme modules and cell-free exozyme biosolutions for synthetic biology manufacturing. The company was formerly known as Invizyne Technologies, Inc. and changed its name to eXoZymes, Inc. in February 2025. eXoZymes, Inc. was incorporated in 2014 and is headquartered in Monrovia... see more

Recent & Breaking News (NDAQ:EXOZ)

eXoZymes Achieves 100× Scale-up of NCT Production Using Exozymes, Demonstrating Near-perfect Feedstock Conversion

ACCESS Newswire December 11, 2025

eXoZymes Provides Third Quarter 2025 Update at 5PM EST Today

ACCESS Newswire November 13, 2025

eXoZymes Announces Cell-Free Biomanufacturing Pioneer, Tyler Korman, As CSO & Amy Lunzer as Chief of Staff

ACCESS Newswire November 13, 2025

eXoZymes to Host Third Quarter 2025 Update on Thursday November 13, 2025, at 5PM EST

ACCESS Newswire November 10, 2025

CEO of eXoZymes on 'AI in Life Sciences' panel at the Beryl Elites' Investment Conference

ACCESS Newswire October 30, 2025

CEO of eXoZymes to Present at Spartan Capital Securities' Second Annual Investor Conference

ACCESS Newswire October 29, 2025

CEO of eXoZymes to Present at ThinkEquity's Annual Investor Conference

ACCESS Newswire October 23, 2025

eXoZymes Inc. Partners With B2i Digital to Spotlight the Cell-Free Next Generation of Biomanufacturing

TheNewsWire October 14, 2025

Driving the Cell-Free Revolution: eXoZymes Leaders Join BioMADE Leadership & Technical Committees

ACCESS Newswire September 30, 2025

eXoZymes Provides Second Quarter 2025 Update at 5PM EST Today

ACCESS Newswire August 12, 2025

eXoZymes to Host Second Quarter 2025 Update on Tuesday August 12, 2025, at 5PM EST

ACCESS Newswire August 7, 2025

eXoZymes Details Biomanufacturing Breakthrough: 4 Grams of NCT with Over 99% Purity

ACCESS Newswire July 29, 2025

eXoZymes Biomanufacturing Breakthrough: From Concept to Gram-Scale NCT in Only 5 Months

ACCESS Newswire July 22, 2025

eXoZymes Selected as Core Industry Partner in $9M NSF-Funded Initiative to Advance Modular Cell-Free Biomanufacturing

ACCESS Newswire June 26, 2025

eXoZymes Highlights Scalable Biomanufacturing Platform and First Spinout, NCTx, on Grow Everything Podcast

ACCESS Newswire May 16, 2025

eXoZymes Provides First Quarter 2025 and NCTx Subsidiary Update at 5PM EST Today

ACCESS Newswire May 12, 2025

eXoZymes to Host First Quarter 2025 and Subsidiary NCTx Update on Monday May 12, 2025, at 5PM EST

ACCESS Newswire May 7, 2025

eXoZymes Launches Subsidiary, NCTx, to Unlock a Promising Compound for Gut and Liver Health

ACCESS Newswire May 6, 2025

Bringing clarity and precision to the cell-free space by introducing exozymes

GlobeNewswire April 21, 2025

BioClick - an enzyme engineering game-changer, launched by eXoZymes and supported by a $300K NIH grant

GlobeNewswire April 10, 2025

Podcasts